Maynard Nexsen Publishes Guidance for Life Sciences Companies in Bloomberg Law Article Series
Maynard Nexsen’s Life Sciences Group has published a comprehensive series of articles in Bloomberg Law designed to help life sciences organizations navigate today’s complex regulatory and business landscape. These resources provide insights for industry leaders on topics ranging from federal regulations and intellectual property to AI-driven innovation and trade secret protection.
The full series includes:
- Considerations for Navigating Current State and Future Federal Regulations of Pharmacy Benefit Managers (PBMs)
- Copyright Issues and Licensing of Technology in Life Sciences
- Due Diligence Concerns For the Buy-Side of Life Sciences Transactions
- Health Care Transactions for Life Sciences Companies
- Protecting Generative AI-Derived Inventions in the Pharmaceutical and Life Science Industry
- State of the 340B Program
- Strategies for Protecting Trade Secrets in the Pharmaceutical and Life Sciences Industries
These articles address critical issues shaping the life sciences sector for executives, legal teams, and compliance professionals seeking to stay ahead of regulatory trends, safeguard intellectual property, and manage risk in an evolving marketplace.
Learn more about Maynard Nexsen’s Life Sciences Group.
About Maynard Nexsen
Maynard Nexsen is a full-service law firm of 600+ attorneys in 31 locations from coast to coast across the United States. Maynard Nexsen formed in 2023 when two successful, client-centered firms combined to form a powerful national team. Maynard Nexsen’s list of clients spans a wide range of industry sectors and includes both public and private companies.
Related Capabilities
